8-K current report · filed Jul 29, 2026

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) 8-K Current Report: July 29, 2026

Item 2.02Item EX-99.1IART overview

Short answer

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Non-GAAP framework covers organic revenue, adjusted EBITDA, adjusted EPS, margins, and net debt for quarter ended June 30, 2026.

INTEGRA LIFESCIENCES HOLDINGS CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Non-GAAP framework covers organic revenue, adjusted EBITDA, adjusted EPS, margins, and net debt for quarter ended June 30, 2026
  • Goodwill impairment reflects heightened risks from tariffs, quality, operational, and supply issues affecting market capitalization
  • Adjusted metrics exclude recurring acquisition, divestiture, restructuring, compliance, transition, and amortization costs
  • Forward guidance lacks GAAP reconciliation because foreign exchange and transaction-related impacts remain materially unpredictable
  • Investors should compare adjusted results with GAAP, given exclusions may recur and obscure ongoing economic costs

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $418.8M, up 0.8% reported and 0.7% organic, signaling modest underlying growth
  • Adjusted EPS $0.56 versus $0.45, while GAAP EPS improved to $0.06 from $(6.31) after prior-year impairment
  • Adjusted EBITDA $78.4M, with margin rising to 18.7% from 17.1%; adjusted gross margin reached 61.3%
  • Specialty Surgery grew 1.7%, offsetting Tissue Reconstruction’s 1.9% decline and continued wound reconstruction weakness
  • 2026 organic growth guidance 0.8%-3.3% and adjusted EPS $2.40-$2.50 reaffirmed; reported revenue range reduced to $1.654B-$1.695B for currency effects
  • Net debt $1.6B and leverage 4.1x remain material constraints despite $10.5M quarterly free cash flow and planned fourth-quarter SurgiMend relaunch

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other INTEGRA LIFESCIENCES HOLDINGS CORP 8-K filings

Get the next IART 8-K as it lands

Follow IART for push alerts, or ask the research agent what this filing means.